FDA Approvals, Stock Price Movements, Published Studies, and Philanthropic Initiatives - Research Report on Johnson & Johnson, Express Scripts, Endo, Biogen and Covidien Editor Note: For more information about this release, please scroll to bottom
NEW YORK, November 18, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Express Scripts Holding Company (NASDAQ: ESRX), Endo Health Solutions Inc. (NASDAQ: ENDP), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Johnson & Johnson Research Report
On November 13, 2013, Janssen Biotech, Inc. (Janssen), part of the Johnson & Johnson family of Companies, announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA[TM] (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The Company said that IMBRUVICA is one of the first medications to receive FDA approval via Breakthrough Therapy Designation pathway; with the approval coming just more than four months after the New Drug Application (NDA) submission was completed in late June 2013. The Company added that IMBRUVICA is being jointly developed and commercialized by Janssen and Pharmacyclics Inc. William Hait, M.D., Ph.D., Global Head, Janssen Research & Development, LLC, said, "The approval of IMBRUVICA is great news for MCL patients who have received prior therapy and the physicians who treat them. The Breakthrough Therapy Designation helped turbo-charge our timelines - it's a remarkable process. It's an excellent example of collaboration between the FDA, Janssen and Pharmacyclics." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Express Scripts Holding Company Research Report
On November 13, 2013, Express Scripts Holding Company's (Express Scripts) stock rose 1.96%, ending the day at $65.93. Over the previous three trading sessions, shares of Express Scripts gained 2.69% compared to the Nasdaq Composite which gained 1.18% during the same period. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Endo Health Solutions Inc. Research Report
On November 13, 2013, Endo Health Solutions Inc.'s (Endo) stock rose 1.37%, ending the day at $64.42. Over the previous three trading sessions, shares of Endo gained 6.48%, outperforming the Nasdaq Composite which gained 1.18% during the same period. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Biogen Idec Inc. Research Report
On November 13, 2013, Biogen Idec Inc. (Biogen) and Swedish Orphan Biovitrum AB (Sobi) announced that Blood, the journal of the American Society of Hematology (ASH), published the detailed phase 3 data for ELOCTATE[TM]- the Companies' investigational long-lasting recombinant factor VIII Fc fusion protein candidate. The Company stated that the results from the A-LONG study showed that people with severe hemophilia A may achieve effective prevention or reduction of bleeding episodes with one or two prophylactic infusions a week. Johnny Mahlangu, M.D., Director of Haemophilia Comprehensive Care Centre, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa, said, "A-LONG is the first clinical study to show that effective control over breakthrough bleeding may be achieved with once- or twice-weekly prophylactic infusions in people with severe hemophilia A." The Company said that if approved, ELOCTATE may benefit individuals with severe hemophilia A by enabling them to receive fewer prophylactic infusions than the current standard of care. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Covidien plc Research Report
On November 11, 2013, Covidien plc (Covidien) announced that it would donate $50,000 for supporting relief efforts in communities affected by Typhoon Haiyan in the Philippines. The Company informed that it is working closely with local and national disaster relief organizations to support the humanitarian aid effort including the Philippines Red Cross, AmeriCares, and DirectRelief. Covidien added that it will provide a corporate grant of $25,000 to the Philippines Red Cross and at least $25,000 worth of products to Direct Relief. According to the Company, all employees in the Philippines are safe, and its offices in manila are undamaged and operational. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner